Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in Dogs
Orocidin, a subsidiary of Nordicus Partners (OTCQB: NORD), has announced positive efficacy results for its lead periodontitis treatment candidate, QR-01, in a preclinical study with dogs. The 13-day small efficacy study, conducted on beagle dogs with clinically confirmed periodontitis, showed consistent improvements across key clinical endpoints including:
- Gingival Index
- Plaque Index
- Overall periodontal Disease
The treatment was well-tolerated with no adverse side effects reported. The company plans to proceed with a human pilot efficacy study scheduled to begin by the end of 2025.
Orocidin, una filiale di Nordicus Partners (OTCQB: NORD), ha annunciato risultati positivi di efficacia per il suo principale candidato al trattamento della parodontite, QR-01, in uno studio preclinico condotto su cani. Lo studio di efficacia di 13 giorni, effettuato su beagle con parodontite clinicamente confermata, ha mostrato miglioramenti costanti in vari parametri clinici chiave, tra cui:
- Indice gengivale
- Indice di placca
- Malattia parodontale complessiva
Il trattamento è stato ben tollerato e non sono stati riportati effetti collaterali avversi. L'azienda prevede di procedere con uno studio pilota di efficacia su esseri umani, che dovrebbe iniziare entro la fine del 2025.
Orocidin, una subsidiaria de Nordicus Partners (OTCQB: NORD), ha anunciado resultados positivos de eficacia para su principal candidato al tratamiento de la periodontitis, QR-01, en un estudio preclínico realizado con perros. El estudio de eficacia de 13 días, realizado en beagles con periodontitis clínicamente confirmada, mostró mejoras consistentes en varios puntos finales clínicos clave, incluyendo:
- Índice gingival
- Índice de placa
- Enfermedad periodontal general
El tratamiento fue bien tolerado y no se reportaron efectos secundarios adversos. La empresa planea proceder con un estudio piloto de eficacia en humanos que comenzará a finales de 2025.
Orocidin은 Nordicus Partners (OTCQB: NORD)의 자회사로, 개를 대상으로 한 전임상 연구에서 주도적인 치주염 치료 후보인 QR-01의 긍정적인 효능 결과를 발표했습니다. 13일 간의 소규모 효능 연구는 임상적으로 확인된 치주염을 앓고 있는 비글 개에서 실시되었으며, 주요 임상 지표 전반에 걸쳐 일관된 개선을 보여주었습니다:
- 치은 지수
- 플라크 지수
- 전체 치주 질병
치료는 잘 견뎌졌으며 부작용은 보고되지 않았습니다. 회사는 2025년 말까지 시작될 예정인 인간 파일럿 효능 연구를 진행할 계획입니다.
Orocidin, une filiale de Nordicus Partners (OTCQB: NORD), a annoncé des résultats d'efficacité positifs pour son principal candidat au traitement de la parodontite, QR-01, dans une étude préclinique menée sur des chiens. L'étude d'efficacité de 13 jours, réalisée sur des beagles présentant une parodontite cliniquement confirmée, a montré des améliorations constantes dans plusieurs critères cliniques clés, notamment :
- Indice gingival
- Indice de plaque
- Maladie parodontal globale
Le traitement a été bien toléré et aucun effet secondaire indésirable n'a été signalé. L'entreprise prévoit de procéder à une étude pilote d'efficacité chez l'homme, dont le début est prévu d'ici la fin de 2025.
Orocidin, eine Tochtergesellschaft von Nordicus Partners (OTCQB: NORD), hat positive Wirksamkeitsergebnisse für ihren führenden Kandidaten zur Behandlung von Parodontitis, QR-01, in einer präklinischen Studie mit Hunden bekannt gegeben. Die 13-tägige kleine Wirksamkeitsstudie, die an Beagle-Hunden mit klinisch bestätigter Parodontitis durchgeführt wurde, zeigte konsistente Verbesserungen in mehreren wichtigen klinischen Endpunkten, darunter:
- Gingivalindex
- Plaqueindex
- Gesamtparodontalerkrankung
Die Behandlung wurde gut vertragen und es wurden keine unerwünschten Nebenwirkungen berichtet. Das Unternehmen plant, mit einer Pilotstudie zur Wirksamkeit beim Menschen fortzufahren, die bis Ende 2025 beginnen soll.
- Successful preclinical efficacy results for QR-01 periodontitis treatment
- No adverse side effects reported during treatment period
- Clear pathway to human trials established for late 2025
- Early-stage preclinical results only, with small sample size
- Human trials not starting for over a year (end of 2025)
BEVERLY HILLS, California, April 02, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, today announced positive efficacy results for its lead periodontitis candidate, QR-01, in a preclinical study involving dogs diagnosed with periodontitis.
The 13-day small efficacy study was conducted on beagle dogs with clinically confirmed periodontitis. and demonstrated consistent improvements across key clinical endpoints, including the Gingival Index, the Plaque Index and overall periodontal Disease. The animals were fasted for a minimum of 8 hours prior to assessment of the efficacy.
Importantly, QR-01 was well tolerated, with no adverse side effects reported throughout the treatment period.
“I am pleased to report that all dogs in the study showed encouraging and consistent responses to the treatment. This represents a significant milestone for Orocidin’s lead product, QR-01 and strengthens our confidence as we prepare for the upcoming human pilot efficacy study, planned to begin by the end of 2025,” said Allan Wehnert, CEO & Founder of Orocidin.
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
hr@nordicuspartners.com
Tel +1 310 666 0750
About Orocidin
Orocidin’s mission is to develop the preferred treatment against aggressive periodontitis. Our innovative therapeutic agent, QR-01, distinguishes itself through its unique ability to provide treatment of both inflammation and bacterial infection.
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
What were the key results of Orocidin's QR-01 periodontitis treatment study for NORD stock?
When will Orocidin (NORD) begin human trials for QR-01 periodontitis treatment?
How long was the preclinical study duration for NORD's QR-01 periodontitis treatment?
What is the relationship between Orocidin and NORD stock?
